Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001479290-22-000036
Filing Date
2022-02-28
Accepted
2022-02-28 17:06:09
Documents
7
Effectiveness Date
2022-02-28

Document Format Files

Seq Description Document Type Size
1 S-8 rvncs-8evergreen2022.htm S-8 91768
2 EX-FILING FEES exhibit107_calculationoffi.htm EX-FILING FEES 20547
3 EX-5.1 exhibit_51opinionofcooleyl.htm EX-5.1 9266
4 EX-23.1 exhibit_231xpwcconsentxrvn.htm EX-23.1 2334
5 EX-99.2 exhibit992_rvncs-82022.htm EX-99.2 70149
6 cooleya03a.jpg GRAPHIC 4382
7 image_0.jpg GRAPHIC 143
  Complete submission text file 0001479290-22-000036.txt   201550
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-263099 | Film No.: 22691160
SIC: 2834 Pharmaceutical Preparations